

Appl. No. : 10/644,277  
Filed : August 19, 2003

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) An isolated human monoclonal antibody that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.
2. (Previously presented) The antibody of Claim 1, further comprising a light chain polypeptide having the sequence of SEQ ID NO.: 64.
- 3.-40. (Cancelled)
- 3 ~~41~~. (Currently amended) An isolated antibody immobilized on an insoluble matrix, wherein the antibody is the antibody of Claim 1.
- 4 ~~42~~. (Withdrawn previously presented) A method for assaying the level of monocyte chemo-attractant protein (MCP-1) in a patient sample, comprising:
  - contacting the anti-MCP-1 antibody of Claim 1 with the patient sample; and
  - detecting the level of MCP-1 in the patient sample.
- 5 ~~43~~. (Withdrawn) A method according to Claim ~~42~~<sup>4</sup>, wherein the patient sample is blood.
- 6 ~~44~~. (Currently amended) A composition, comprising the antibody ~~or fragment thereof~~ of Claim 1, and a pharmaceutically acceptable carrier.
- 7 ~~45~~. (Withdrawn amended) A method of effectively treating a neoplastic disease, comprising:
  - selecting an animal in need of treatment for a neoplastic disease; and
  - administering to said animal a therapeutically effective dose of the antibody of Claim 1.
- 8 ~~46~~. (Withdrawn amended) The method of Claim ~~45~~<sup>7</sup>, wherein said neoplastic disease is selected from the group consisting of: breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, stomach cancer, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and ~~prostrate~~ prostate cancer.
47. (Withdrawn amended) A method of effectively treating inflammatory conditions, comprising:
  - selecting an animal in need of treatment for an inflammatory condition; and
  - administering to said animal a therapeutically effective dose of the antibody of Claim 1.

Appl. No. : 10/644,277  
Filed : August 19, 2003

48. (Withdrawn) The method of Claim 47, wherein said inflammatory condition is selected from the group consisting of: rheumatoid arthritis, glomerulonephritis, atherosclerosis, psoriasis, restenosis, autoimmune disease, and multiple sclerosis.

49. (Cancelled)

50. (Cancelled)

9 ~~51~~. (Currently amended) An isolated human monoclonal antibody that binds to the sequence ISVQRLASYRRITSSK (SEQ ID NO.: 150).

52. (Cancelled)

10 ~~53~~. (Previously presented) A method of manufacturing the antibody of Claim 1, comprising:

immunizing a mammal with a synthetic peptide of MCP-1;

recovering a lymphatic cell that expresses the antibody of Claim 1 from the immunized mammal; and

fusing the lymphatic cell with a myeloid-type cell to prepare a hybridoma cell that produces the antibody of Claim 1.

11 ~~54~~. (New) The antibody of Claim 1, wherein said antibody is conjugated to a therapeutic agent.

12 ~~55~~. (New) The antibody of Claim <sup>11</sup>~~54~~, wherein said therapeutic agent is a toxin.

13 ~~56~~. (New) The antibody of Claim <sup>12</sup>~~55~~, wherein said toxin is an immunotoxin.

14 ~~57~~. (New) The antibody of Claim <sup>11</sup>~~54~~, wherein said therapeutic agent is a chemotherapeutic agent.

15 ~~58~~. (New) The antibody of Claim <sup>14</sup>~~57~~, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.

16 ~~59~~. (New) The antibody of Claim <sup>11</sup>~~54~~, wherein said therapeutic agent is a steroid.

17 ~~60~~. (New) The antibody of Claim <sup>11</sup>~~54~~, wherein said therapeutic agent is a radioisotope.

18 ~~61~~. (New) The antibody of Claim <sup>17</sup>~~60~~, wherein said radioisotope is selected from the group consisting of <sup>3</sup>H, <sup>14</sup>C, <sup>15</sup>N, <sup>35</sup>S, <sup>90</sup>Y, <sup>99</sup>Tc, <sup>111</sup>In, <sup>125</sup>In, and <sup>131</sup>I.

19 ~~62~~. (New) The antibody of Claim <sup>9</sup>~~51~~, wherein said antibody is conjugated to a therapeutic agent.

20 ~~63~~. (New) The antibody of Claim <sup>19</sup>~~62~~, wherein said therapeutic agent is a toxin.

Appl. No. : 10/644,277  
Filed : August 19, 2003

- 21 ~~64~~. (New) The antibody of Claim ~~63~~<sup>20</sup>, wherein said toxin is an immunotoxin.
- 22 ~~65~~. (New) The antibody of Claim ~~63~~<sup>20</sup>, wherein said therapeutic agent is a chemotherapeutic agent.
- 23 ~~66~~. (New) The antibody of Claim ~~65~~<sup>22</sup>, wherein said chemotherapeutic agent is selected from the group consisting of taxol, doxorubicin, cis-platinum, and 5-fluorouracil.
- 24 ~~67~~. (New) The antibody of Claim ~~65~~<sup>22</sup>, wherein said therapeutic agent is a steroid.
- 25 ~~68~~. (New) The antibody of Claim ~~65~~<sup>22</sup>, wherein said therapeutic agent is a radioisotope.
- 26 ~~69~~. (New) The antibody of Claim ~~68~~<sup>25</sup>, wherein said radioisotope is selected from the group consisting of  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{15}\text{N}$ ,  $^{35}\text{S}$ ,  $^{90}\text{Y}$ ,  $^{99}\text{Tc}$ ,  $^{111}\text{In}$ ,  $^{125}\text{In}$ , and  $^{131}\text{I}$ .
- 27 ~~70~~. (New) The antibody of Claim 1, wherein said antibody neutralizes the activity of MCP-1.
- 28 ~~71~~. (New) The antibody of Claim ~~41~~<sup>3</sup>, wherein said antibody neutralizes the activity of MCP-1.
- 29 ~~72~~. (New) The antibody of Claim ~~51~~<sup>9</sup>, wherein said antibody neutralizes the activity of MCP-1.
- 30 ~~73~~. (New) The antibody of Claim 1, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
- 31 ~~74~~. (New) The antibody of Claim ~~73~~<sup>30</sup>, wherein said dissociation constant is 3.3 pM.
- 32 ~~75~~. (New) The antibody of Claim ~~41~~<sup>3</sup>, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
- 33 ~~76~~. (New) The antibody of Claim ~~75~~<sup>32</sup>, wherein said dissociation constant is 3.3 pM.
- 34 ~~77~~. (New) The antibody of Claim ~~51~~<sup>9</sup>, wherein said antibody binds to MCP-1 with a dissociation constant ( $K_D$ ) of approximately 3.0 pM.
- 35 ~~78~~. (New) The antibody of Claim ~~77~~<sup>34</sup>, wherein said dissociation constant is 3.3 pM.
- 36 ~~79~~. (New) An isolated human monoclonal antibody binding fragment that binds to MCP-1 and comprises a heavy chain polypeptide having the sequence of SEQ ID NO.: 62.
- 37 ~~80~~. (New) The antibody binding fragment of Claim ~~79~~<sup>36</sup>, further comprising a light chain polypeptide having the sequence of SEQ ID NO.: 64.
- 38 ~~81~~. (New) The antibody binding fragment of Claim ~~79~~<sup>36</sup>, wherein said binding fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub>, and F<sub>v</sub>.

Appl. No. : 10/644,277  
Filed : August 19, 2003

<sup>36</sup>  
~~39~~<sup>82</sup>. (New) The antibody binding fragment of Claim ~~79~~<sup>36</sup>, wherein said fragment is conjugated to a therapeutic agent.